Among these, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and bariatric surgery (BS) have shown promising effects on weight loss, insulin sensitivity and hepatic fat reduction, positioning them as potential interventions for mitigating NASH progression [6]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.